Coronary Heart Disease (CHD), a group of clinical syndromes caused by the development of coronary atherosclerosis, has become the main cause of death in human. The effect of traditional drugs or invasive treatment has encountered a bottleneck. Recent studies have shown that CHD, including coronary atherosclerosis, myocardial infarction, myocardial ischemia-reperfusion injury, are defined as a kind of inflammatory diseases. Inflammatory factors, cytokines involved in inflammatory response, have gradually become an important biomarker of CHD and effective target for treatment, including anti-inflammatory factors and pro-inflammatory factors. In recent years, the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) has found that IL-1β Antibody could significantly improve the long-term prognosis of patients with coronary heart disease, screening by high CRP, indicating a milestone in the anti-inflammatory treatment of CHD.
In this Research Topic, we would like to create a forum for discussions on: the cellular and molecular mechanisms of inflammatory factors in CHD, the effects of inflammatory factors on CHD, inflammatory factors as biomarkers of CHD, as well as pathophysiological and clinical outcomes of CHD therapeutics by targeting inflammatory factors.
We welcome papers in the following subtopics, but not limited to:
1) Studies on circulating and tissue anti-inflammatory factors or pro-inflammatory factors in patients with CHD.
2) Analysis on the relationship between inflammatory biomarkers and CHD.
3) Treatment effects by targeting inflammatory factors on atherosclerosis.
4) Treatment effects and mechanisms of inflammatory factors on myocardial ischemia, including myocardial infarction and myocardial ischemia reperfusion injury.
5) New techniques or carriers for inflammatory factors in treatment for CHD, such as nanoparticles.
Coronary Heart Disease (CHD), a group of clinical syndromes caused by the development of coronary atherosclerosis, has become the main cause of death in human. The effect of traditional drugs or invasive treatment has encountered a bottleneck. Recent studies have shown that CHD, including coronary atherosclerosis, myocardial infarction, myocardial ischemia-reperfusion injury, are defined as a kind of inflammatory diseases. Inflammatory factors, cytokines involved in inflammatory response, have gradually become an important biomarker of CHD and effective target for treatment, including anti-inflammatory factors and pro-inflammatory factors. In recent years, the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) has found that IL-1β Antibody could significantly improve the long-term prognosis of patients with coronary heart disease, screening by high CRP, indicating a milestone in the anti-inflammatory treatment of CHD.
In this Research Topic, we would like to create a forum for discussions on: the cellular and molecular mechanisms of inflammatory factors in CHD, the effects of inflammatory factors on CHD, inflammatory factors as biomarkers of CHD, as well as pathophysiological and clinical outcomes of CHD therapeutics by targeting inflammatory factors.
We welcome papers in the following subtopics, but not limited to:
1) Studies on circulating and tissue anti-inflammatory factors or pro-inflammatory factors in patients with CHD.
2) Analysis on the relationship between inflammatory biomarkers and CHD.
3) Treatment effects by targeting inflammatory factors on atherosclerosis.
4) Treatment effects and mechanisms of inflammatory factors on myocardial ischemia, including myocardial infarction and myocardial ischemia reperfusion injury.
5) New techniques or carriers for inflammatory factors in treatment for CHD, such as nanoparticles.